Papel da resistência genotípica à nova classe de medicamentos que atuam na integrase no resgate terapêutico de pacientes infectados pelo HIV-1

FDA. FDA approves new HIV drug – Raltegravir tablets used in combination with other antiretroviral agents. In: Adminis tration USFaD, editor. FDA News, 2007.

Ministério da Saúde, 2009. Disponível em: http://www.aids. gov.br. Acesso em: 30 de março de 2011.

Markovitz, M. Targeting Integrase: Mechanisms of Action and Mechanisms of Resistance to Integrase Inhibitors. Clini cal Care Options; 2008.

Charpentier C, Karmockine M, Laureillard D, Tisserand P, Belec L, Weiss L, Si-Mohamed A, Picketti C. Drug resistance profiles for the HIV Integrase gene in patients failing Ralte gravir salvage therapy.HIV Med. 2008; v.9, p. 765-770.

Hu Z e Kuritzkes. D.R. Effect of Raltegravir Resistance Muta tions in HIV-1 Integrase on Viral Fitness. J Acquir Immune Defic Syndr. 2010; v. 55, p. 148-155.

Hackett JJ, Swanson P, Harris B, Holzmayer V, Yamaguchi J, Bodelle P, Brennan C, Schochetman G e Devare S. Conf Retr. Opportunistic Infect. Comprehensive evaluation of HIV-1 integrase gene diversity in group m, n, and o viruses. Abstract 366, 2005; Feb 22-25